Drug Profile
Levosulpiride
Alternative Names: L-sulpiride; Levobren; Levopraid; Levosulpride; RV-12309Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Ravizza Farmaceutici
- Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastroparesis; Major depressive disorder; Nausea and vomiting; Psychotic disorders
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 04 Aug 2003 Data presented at the Digestive Disease Week - 2003 (DDW-2003) have been added to the Peptic Ulcer Disease therapeutic trials section
- 24 Jul 2003 Levosulpiride is available for licensing in the Far East and Africa (http://www.it.basf-pharma.com)